When: Price at or below $89.50 (1.5 ATR below current price)

Then: Hard stop - exit all positions

Trim 25-33% into $96-$98 resistance; hold core position; wait for Q2 confirmation before adding; add at $87-$89 support if setup improves.

• $6.41 EPS consensus requires 72% beat on FY26's $3.73 actual—peak case, not base case
• Aggressive analyst's $5.50-$5.80 realistic estimate is still 47-58% jump from $3.73 FY26
• Q1 organic growth closer to 8% when stripped of $570M extra selling week impact (not 13.7% headline)
• Bear case $4.00-$4.50 implies stock at 21-23x earnings with no multiple expansion left
• Working capital deteriorated $1.4B in FY26 at a company with historically stable working capital
• Inventory at $5.95B vs $5.48B prior year ($475M build); management offers no explanation in commentary
• Construction in progress at $2.4B for capacity but doesn't explain inventory specifically
• MACD histogram negative since August 25; MACD line below signal line for 3 weeks
• RSI cooled from 75 to 60 after vertical move—interpreted as buyer exhaustion, not healthy reset
• Stock rallied 29% in roughly 3 months, now pressing $94.50-$96 resistance
• MACD/technical deterioration makes full-size position risky into uncertain catalyst
• Intuitive Surgical deceleration in robotic procedure growth is TAM signal for entire surgical robotics space including MDT Hugo ramp
• CMS TAVR expansion primarily benefits Edwards; MDT gets only small spillover
• Dividend near $3.6B absolute terms since FY23; growth from buybacks not payout increases
• 10-year Treasury briefly touched 5%; Polymarket pricing 94% probability of zero Fed cuts in 2026
• 3.17% yield offers negative real yield before inflation vs 5% risk-free rate
• Q2 comp gets materially harder; if Q2 prints 4-6% organic vs expected 7-9%, thesis cracks
• MiniMed separation creates execution noise; market often sells stub and waits for dust to settle
• Bull case requires perfect execution AND multiple expansion AND benign macro simultaneously—much higher bar than bear case

→ vs aggressive: Bull case requires perfect execution AND multiple expansion AND benign macro simultaneously—far higher bar than bear case which only needs one product ramp stumble or FX reversal

→ vs aggressive: The $6.41 EPS consensus is a peak case requiring 72% beat on FY26's $3.73, not a base case; aggressive analyst's own $5.50-$5.80 estimate still requires 47-58% jump

→ vs aggressive: Q1 organic growth was 8%, not 13.7%—stripping the $570M extra selling week impact reveals meaningful deceleration from headline

→ vs aggressive: Working capital deterioration of $1.4B and $475M inventory build cannot be explained by capacity expansion alone; demand softening or channel stuffing are real risks

→ vs aggressive: Negative MACD histogram since August 25 is active momentum deterioration, not a coiled spring; RSI cooling from 75 to 60 is buyer exhaustion, not healthy reset

→ vs aggressive: Intuitive Surgical's procedure growth deceleration is a TAM signal for entire surgical robotics space, not bullish for MDT followers

→ vs aggressive: 3.17% dividend yield offers negative real yield vs 5% Treasuries; dividend growth has been flat with growth from buybacks not payout increases

→ vs aggressive: Q2 comp materially harder; if Q2 prints 4-6% organic vs expected 7-9%, thesis cracks—but full position at risk if it does

→ vs aggressive: MiniMed separation creates execution noise; market often sells stub during spin mechanics leading to sideways or down trading before any re-rating

→ vs aggressive: Trim at $96-$98 resistance is not leaving money on table—it is locking gains, reducing position risk into uncertain catalyst, and creating dry powder

HOLD with tiered trim: sell 15-20% of position on daily close above $96 with volume confirmation; hold core through Q2; add back trimmed portion only on pullback to $90-92 zone IF Q2 confirms 7-9% organic growth without inventory accumulation and MACD histogram flips above zero. Use ATR-based stop at ~$90.30 ($89-90 zone).

• TTM EPS is $4.06; street consensus of $6.41 is not management's number—it extrapolates from a quarter with a $570M calendar tailwind and requires ~8% organic growth through difficult comps
• Working capital deterioration of $1.4B in a single fiscal year is not a rounding error; inventory build interpretation is ambiguous until Q2 data
• MACD histogram negative for three weeks is a real momentum deterioration signal regardless of broader uptrend structure
• Q1 cardiovascular acceleration of ~8% underlying organic growth is roughly double MDT's historical 3-4% baseline—a structural shift if real, not just a one-quarter beat
• ISRG deceleration is in US robotic procedures (mature market); MDT's Hugo is in early commercial stages internationally with different dynamics
• MiniMed standalone Q1 of plus 15.8% revenue growth validates the spin thesis
• MDT beta is 0.57—one of the most defensive names in med-tech; dividend at 3.17% yield provides real downside support but is not a primary thesis driver
• ATR is $2.34; 1.5 ATR stop sits at ~$90.30, aligning with lower Bollinger band at $89.75 and 50 SMA at $87.90
• 50 and 200 SMA confluence at $87.90 and $88.51 makes that a structurally important level for potential addition
• MDT is a defensive, low-beta quality compounder with near-term catalyst path—appropriate as portfolio ballast, not high-conviction momentum position

→ vs aggressive: The $6.41 EPS consensus is not management's number—it is the analyst community extrapolating aggressively from a quarter with a $570M calendar tailwind. TTM EPS is $4.06 and management's own FY27 guidance only puts the low end modestly above that. The bull case requires perfect execution, multiple expansion, AND benign macro all at once—stacked 'ifs' dismissed too casually as 'anchors-on-history' thinking

→ vs aggressive: Working capital deterioration of $1.4B in a single fiscal year is not a rounding error. Management raising guidance while sitting on rising inventory could mean they're supporting a softer-than-headline quarter, not demand health. Calling $475M 'not a thesis-breaker at $120B market cap' is survivorship bias dressed up as analysis—true risk management requires assuming the ambiguous signal could be the worst-case interpretation

→ vs aggressive: MACD histogram negative for three weeks is, by definition, momentum deteriorating for three weeks. Dismissing this as 'overbought-contrarian-indicator nonsense' is bluster, not analysis. The broader structure may remain constructive, but overconfidence in momentum trends costs money when they actually turn

→ vs conservative: The conservative analyst treats the Q1 ~8% underlying organic growth as dismissible versus the 3-4% historical baseline, but this is actually a massive structural acceleration if real. Cardiovascular segment outperforming the rest of med-tech is a multi-quarter story, and Wells Fargo commentary on PFA, robotics, and ablation suggests the product cycle is real. Assuming any one product ramp stumbles reverses this is conflating possibility with probability

→ vs conservative: ISRG's deceleration is in US robotic procedures—a mature market with penetration concerns. MDT's Hugo is in early commercial stages internationally where dynamics are different. The TAM signal reading is plausible for the long term but doesn't directly threaten the Hugo ramp in the next two to three quarters

→ vs conservative: Calling MiniMed separation 'execution noise' that historically causes stub selloffs is fair as a base case, but MMED's standalone Q1 of plus 15.8% revenue growth is a legitimate validation of the spin thesis. The conservative analyst frames this as an obvious negative when it is not